JESÚS JERÓNIMO PINTOR JUST-rekin lankidetzan egindako argitalpenak (35)

2022

  1. Therapeutic potential of topical administration of siRNAs against HIF-1α for corneal neovascularization

    Experimental Eye Research, Vol. 219

2020

  1. Optimization of a Rabbit Dry Eye Model Induced by Topical Instillation of Benzalkonium Chloride

    Journal of Ophthalmology, Vol. 2020

2019

  1. Effect of Melatonin and Its Analogs on Tear Secretion

    The Journal of pharmacology and experimental therapeutics, Vol. 371, Núm. 1, pp. 186-190

2017

  1. Low expression of CD39 and CD73 genes in centenarians compared with octogenarians

    Immunity and Ageing, Vol. 14, Núm. 1

  2. The role and therapeutic potential of melatonin in age-related ocular diseases

    Journal of Pineal Research, Vol. 63, Núm. 2

  3. Understanding the presence and roles of Ap4A (Diadenosine tetraphosphate) in the eye

    Journal of Ocular Pharmacology and Therapeutics, Vol. 33, Núm. 6, pp. 426-434

2016

  1. The role of dinucleoside polyphosphates on the ocular surface and other eye structures

    Progress in Retinal and Eye Research, Vol. 55, pp. 182-205

2015

  1. Effect of melatonin and analogues on corneal wound healing: Involvement of Mt<inf>2</inf> melatonin receptor

    Current Eye Research, Vol. 40, Núm. 1, pp. 56-65

  2. Melatonin receptors trigger cAMP production and inhibit chloride movements in nonpigmented ciliary epithelial cells

    Journal of Pharmacology and Experimental Therapeutics, Vol. 352, Núm. 1, pp. 119-128

  3. Signs and symptoms of dry eye in keratoconus patients: A pilot study

    Current Eye Research, Vol. 40, Núm. 11, pp. 1088-1094

2014

  1. An update on dry eye disease molecular treatment: Advances in drug pipelines

    Expert Opinion on Pharmacotherapy, Vol. 15, Núm. 10, pp. 1371-1390

2013

  1. Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: Significance for combination therapy in glaucoma

    Journal of Pharmacology and Experimental Therapeutics, Vol. 346, Núm. 1, pp. 138-145

2012

  1. Involvement of carbonic anhydrases in the ocular hypotensive effect of melatonin analogue 5-MCA-NAT

    Journal of Pineal Research, Vol. 52, Núm. 3, pp. 265-270

  2. Ocular disorders and the utility of animal models in the discovery of melatoninergic drugs with therapeutic potential

    Expert Opinion on Drug Discovery, Vol. 7, Núm. 10, pp. 989-1001

  3. Potential role of Rho-associated protein kinase inhibitors for glaucoma treatment

    Recent Patents on Endocrine, Metabolic and Immune Drug Discovery, Vol. 6, Núm. 2, pp. 89-98

  4. Recent patents and developments in glaucoma biomarkers

    Recent Patents on Endocrine, Metabolic and Immune Drug Discovery, Vol. 6, Núm. 3, pp. 224-234

  5. Silencing of P2Y 2 receptors reduces intraocular pressure in New Zealand rabbits

    British Journal of Pharmacology, Vol. 165, Núm. 4 B, pp. 1163-1172

  6. Update in glaucoma medicinal chemistry: Emerging evidence for the importance of melatonin analogues

    Current Medicinal Chemistry, Vol. 19, Núm. 21, pp. 3508-3522

2011

  1. Phospholipase C/protein kinase C pathway is essential for corneal re-epithelialization induced by Ap 4A

    Current Eye Research, Vol. 36, Núm. 12, pp. 1108-1115

  2. Regulation of ocular adrenoceptor genes expression by 5-MCA-NAT: Implications for glaucoma treatment

    Pharmacogenetics and Genomics, Vol. 21, Núm. 9, pp. 587-589